Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- San Francisco, California
- Most recent report
- 8-K, filed Sep 8, 2026
- Incorporated
- Delaware
- Filings on record
- 1,000+ filings
- On EDGAR
- CIK 906709
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer, Smaller reporting company
Financials 8 of 45
News 8 of 164
- 8-K Current report on a material event Sep 8, 2026
- 8-K Quarterly results Aug 13, 2026
- 8-K Shareholder vote results Jun 5, 2026
- 8-K Leadership change May 8, 2026
- 8-K Quarterly results May 7, 2026
- 8-K Significant contract Apr 23, 2026
- 8-K Current report on a material event Apr 20, 2026
- 8-K Other events Apr 20, 2026
Prospectuses and Registrations 8 of 26
- S-8 Registration statement for an employee plan Aug 14, 2026
- 424B5 Prospectus supplement for an offering May 8, 2026
- 424B5 Prospectus supplement for an offering Apr 23, 2026
- 424B5 Prospectus supplement for an offering Apr 20, 2026
- 424B5 Prospectus supplement for an offering Feb 13, 2026
- 424B5 Prospectus supplement for an offering Feb 10, 2026
- S-8 Registration statement for an employee plan Nov 12, 2025
- 424B5 Prospectus supplement for an offering Nov 12, 2025
Proxies 8 of 22
- DEFA14A Extra proxy material Apr 24, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 24, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 25, 2025
- PRE 14A Preliminary proxy statement Apr 15, 2025
- DEFA14A Extra proxy material Apr 26, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 26, 2024
- DEFA14A Extra proxy material Apr 28, 2023
- DEF 14A Proxy statement for a shareholder vote Apr 28, 2023
Ownership 8 of 713
- 4 Insider reported a trade Aug 20, 2026
- 4 Insider reported a trade Aug 20, 2026
- 144 Notice of a proposed sale of restricted stock Aug 18, 2026
- 144 Notice of a proposed sale of restricted stock Aug 18, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G Large holder reported a passive stake Jul 31, 2026
- SCHEDULE 13G Large holder reported a passive stake Jul 29, 2026
Other 8 of 30
- ARS Annual report sent to shareholders Apr 24, 2026
- ARS Annual report sent to shareholders Apr 25, 2025
- EFFECT Notice that a registration became effective Apr 1, 2025
- CORRESP Reply to SEC staff Mar 28, 2025
- UPLOAD Comment letter from SEC staff Mar 20, 2025
- DRSLTR Mar 14, 2025
- DRS Draft registration statement, submitted confidentially Mar 14, 2025
- EFFECT Notice that a registration became effective Jun 5, 2024
Everything here comes from Nektar Therapeutics's own filings on SEC EDGAR. The filing list is rechecked every hour.